+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 25 Actively Recruiting clinical trials

O

Actively Recruiting

Researchers are evaluating the safety and effects of marstacimab, a study medicine, for treating hemophilia in male pediatric patients aged 1 to 17 years. The study focuses on severe Hemophilia A and moderately severe to severe Hemophilia B, including participants with or without inhibitors. Enrollment is done sequentially by age groups starting with adolescents, then children aged 6 to 11 years, followed by children aged 1 to 5 years. All participants will receive weekly subcutaneous injections of marstacimab, initially administered at the study site with subsequent doses given either at home or at the study site over a 12-month treatment period. The study compares participants experiences during treatment to their historical bleeding and treatment records to assess how marstacimab may help prevent bleeding episodes common in hemophilia. Participants will be involved for about 14 months, including a screening period of roughly one month, 12 months of treatment, and a one-month follow-up. They will attend at least 10 study visits, with the option of completing two visits at home if regulations allow, and receive six scheduled phone calls approximately every two months. Researchers will monitor bleeding rates, safety events, immune responses, joint health, and quality of life during this time.

Age: 1Year - 17YearsMALEPhase 3
63 locations
E

Actively Recruiting

Researchers are evaluating the efficacy and safety of elecoglipron for weight management in adults living with obesity or overweight. This Phase III global study includes two independent, randomized, double-blind, placebo-controlled pivotal studies. Study 1 involves adults without type 2 diabetes mellitus T2DM, while Study 2 includes adults with T2DM. Participants have obesity or overweight with at least one weight-related comorbidity such as hypertension, prediabetes, dyslipidemia, cardiovascular disease, or obstructive sleep apnea. Participants will be randomly assigned to receive one of two doses of elecoglipron or a placebo once daily as oral tablets. The treatment lasts 72 weeks, and the study is conducted in multiple centers worldwide. The primary measure is the percentage change in body weight from baseline at 72 weeks. Secondary measures include absolute weight loss, achievement of specific weight loss percentages, waist circumference reduction, glycemic control, and systolic blood pressure reduction. Throughout the study, participants will undergo regular assessments including body weight and waist measurements, laboratory tests related to glycemic control, and blood pressure monitoring. Researchers will also track the achievement of normoglycemia and glycemic control in participants with elevated HbA1c levels. Safety and efficacy data will be collected until the study completion in 2029, with participants monitored closely during the 72-week treatment period.

Age: 18Years +All GendersPhase 3
325 locations
O

Actively Recruiting

Diffuse large B-cell lymphoma DLBCL is the most common and aggressive subtype of non-Hodgkin lymphoma NHL, affecting many patients with rapid tumor growth and symptoms depending on tumor location. This observational study aims to understand the clinical characteristics, treatment patterns, and access to new therapies for patients with DLBCL in the Middle East and Africa region, including both newly diagnosed and relapsed or refractory cases. Participants are grouped into two cohorts those who are newly diagnosed and eligible for treatment, and those who have relapsed or are refractory after at least one prior therapy. The study does not involve experimental treatments but collects information on how patients are treated in real-world settings and explores access to innovative therapies. During the study, patient demographics, disease characteristics, risk profiles, and treatment patterns are documented over 22 months. Researchers will gather data through reviews of medical records and clinical information without administering treatments. The primary goal is to describe first-line and subsequent treatment approaches and to understand patient access to novel therapies for DLBCL.

All AgesAll Genders
21 locations
S

Actively Recruiting

This research aims to evaluate the effectiveness, safety, and tolerability of combining baxdrostat with dapagliflozin compared to dapagliflozin alone in people with chronic kidney disease CKD and high blood pressure. The goal is to reduce the risk of serious kidney problems, heart failure events, or cardiovascular death. This is a phase III, international, multicenter, randomized, double-blind, placebo-controlled, event-driven study focused on treatment outcomes. Participants who do not already use SGLT2 inhibitors will first undergo a 4-week dapagliflozin run-in period. After that, they will be randomly assigned to receive either baxdrostat plus dapagliflozin or placebo plus dapagliflozin. Baxdrostat dosing may start low and be increased if needed. Study visits will occur frequently early on at 2, 4, 8, 16, 34, and 52 weeks post-randomization, then approximately every 4 months. The study will end when a predetermined number of kidney or cardiovascular events occur. During the study, participants will have scheduled visits for assessments including kidney function, heart health, and safety monitoring. If they stop the study treatment early, they will continue on dapagliflozin alone and remain in the trial for follow-up visits. Researchers will measure outcomes such as sustained kidney function decline, kidney failure, heart failure events, cardiovascular death, and all-cause death over up to 37 months. Data collection continues until the study closes, with safety and tolerability closely observed throughout.

Age: 18Years +All GendersPhase 3
771 locations
R

Actively Recruiting

Researchers are evaluating luspatercept treatment in adults with transfusion-dependent beta-Thalassemia in the Middle East. This observational study aims to understand how luspatercept affects the need for blood transfusions and hemoglobin levels in real-world clinical settings. The study is sponsored by Bristol-Myers Squibb and focuses on adults who have started luspatercept treatment within the past year. Participants receive luspatercept as prescribed according to the product label, with no experimental intervention assigned by the study. The study observes ongoing treatment and collects data retrospectively and prospectively, following participants for up to 144 weeks. Key measurements include changes in transfusion burden, pre-transfusion hemoglobin, and iron levels, among other clinical and healthcare utilization outcomes. During the study, participants provide signed consent and allow researchers to collect medical data relevant to their treatment with luspatercept. Researchers monitor transfusion visits, hemoglobin levels, treatment duration, dose adjustments, and other health indicators. The study includes comprehensive data collection on participants disease characteristics, comorbidities, and treatment history, aiming to provide a detailed understanding of luspatercepts use over nearly three years.

Age: 18Years +All Genders
13 locations
S

Actively Recruiting

This research aims to evaluate how a robotic mental health simulation can improve professional identity, interpersonal communication skills, and emotional intelligence among nursing students in Saudi Arabia. The study focuses on undergraduate nursing students enrolled in a psychiatric-mental health nursing course, addressing the need for enhanced skills in therapeutic relationships and emotional awareness in mental health nursing. The study uses a quasi-experimental design with pre-test, post-test, and three-month follow-up assessments to measure both immediate and sustained effects of the intervention. Participants are divided into two groups an intervention group that engages in structured simulation sessions with a robot portraying patients with psychiatric conditions, and a control group receiving traditional teaching methods without robotic simulation. The simulation includes scenarios involving anxiety, depression, psychosis, emotional distress, and aggressive behavior, with each session comprising pre-briefing, active interaction, and faculty-guided debriefing to support learning and reflection. During the study, participants complete validated self-report measures on professional identity, communication competence, and emotional intelligence before the intervention, immediately after, and at three months post-intervention. The study monitors attendance and completion of assessments to evaluate the educational impact of the robotic simulation. Findings will help determine the value of this innovative teaching method in preparing future nurses with essential psychological and interpersonal skills.

Age: 17Years - 27YearsAll GendersPhase Not Applicable
1 location
P

Actively Recruiting

Researchers are evaluating the efficacy and safety of orforglipron in adults with type 2 diabetes T2D who participate in fasting during the month of Ramadan. This Phase 3b, open-label study involves participants between 18 and 65 years old with T2D, aiming to understand how the drug performs in this fasting population. Participants will receive orforglipron orally as the study treatment. The study is a single-arm design without placebo control, and it takes place across multiple countries and centers. Each participants involvement lasts up to 48 weeks and includes both in-clinic and virtual visits. During the study, participants will attend a minimum of 7 clinic visits and 4 virtual visits. Researchers will monitor changes in hemoglobin A1c HbA1c levels from baseline through up to 8 weeks after the start of Ramadan fasting. Other assessments include fasting serum glucose, body weight, and quality of life measures. The study tracks safety and efficacy outcomes throughout the participation period.

Age: 18Years - 65YearsAll GendersPhase 3
40 locations
P

Actively Recruiting

Researchers are investigating the efficacy and safety of golcadomide combined with rituximab compared to investigators choice treatments in adults with relapsed or refractory follicular lymphoma who have received at least one prior systemic therapy. This multicenter, randomized, open-label Phase 3 study focuses on participants with confirmed follicular lymphoma that has returned or not responded to previous treatments, aiming to better understand treatment options in this setting. Participants will be randomly assigned to receive either golcadomide plus rituximab or one of the investigators chosen regimens, which may include rituximab combined with lenalidomide, R-CHOP chemotherapy rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisoneprednisolone, or rituximab with bendamustine. Each treatment involves specified doses on specified days, and the study compares these approaches over a treatment period. During the study, participants will be closely monitored through evaluations such as imaging scans, pathology reviews, and quality of life questionnaires. Researchers will assess progression-free survival up to approximately 32 months, along with other measures like overall response rate, overall survival, duration of response, and minimal residual disease status. Safety and treatment effects will be tracked, and participants may be followed for up to nearly seven years to gather comprehensive outcome data.

Age: 18Years +All GendersPhase 3
160 locations
P

Actively Recruiting

Researchers are comparing the effects of two treatment combinations in adults with stage IV or recurrent non-squamous non-small cell lung cancer NSCLC that has a PD-L1 expression of 1% or higher. This phase 3 trial investigates whether Nivolumab and Relatlimab combined with chemotherapy works differently than Pembrolizumab with chemotherapy as first-line treatment for this condition. The study is sponsored by Bristol-Myers Squibb and uses a randomized parallel design. Participants will be assigned to one of two groups one group receives Nivolumab and Relatlimab with chemotherapy drugs, while the other group receives Pembrolizumab with chemotherapy. Chemotherapy may include drugs such as Carboplatin, Pemetrexed, or Cisplatin, given at specified doses on specific days. Treatment schedules and doses are carefully planned, and participants are treated during the trial period. During the study, participants undergo regular assessments to measure overall survival, progression-free survival, response rates, and duration of response, with follow-up lasting up to five years. Researchers also track adverse events and immune-related side effects for up to 2.5 years. Quality of life is monitored through symptom questionnaires. Assessments include imaging scans and laboratory tests to evaluate disease status and treatment effects. The total duration of participation may extend over several years to capture long-term outcomes and safety.

Age: 18Years +All GendersPhase 3
329 locations
R

Actively Recruiting

Researchers are evaluating the efficacy, safety, pharmacokinetics PK, and pharmacodynamics PD of atumelnant in adults with classic congenital adrenal hyperplasia CAH caused by 21-hydroxylase deficiency 21-OHD. This Phase 3, global, multicenter, randomized, double-blind, placebo-controlled study involves adults aged 18 to under 75 years who have been on a stable glucocorticoid GC regimen for at least 2 months. The study aims to understand how atumelnant works and how safe it is for this population. Participants will be randomly assigned in a 21 ratio to receive either atumelnant tablets or a matching placebo once daily for 32 weeks. The atumelnant dose starts at 80 mg daily with an option to increase to 120 mg daily at Week 20 if needed. Before treatment, participants undergo a 3- to 6-week screening period to confirm eligibility. Approximately 150 participants may take part worldwide. During the study, participants will have regular assessments including hormone level measurements such as morning post-GC androstenedione A4 to evaluate response. Researchers will monitor glucocorticoid doses, safety, and other health indicators. The main outcome is the proportion of participants achieving morning post-GC A4 levels at or below the upper limit of normal while on physiologic GC replacement at Week 32. The total participation time includes screening plus 32 weeks of treatment and evaluations.

Age: 18Years - 74YearsAll GendersPhase 3
75 locations

1-10 of 25

1